Last updated: February 18, 2026
This analysis examines the patent protection, regulatory status, and projected market trajectory for the pharmaceutical product identified by National Drug Code (NDC) 00173-0772. The focus is on identifying key intellectual property (IP) assets, understanding their expiration timelines, and forecasting commercial performance based on these factors and prevailing market dynamics.
What is the Regulatory Status of NDC 00173-0772?
NDC 00173-0772 corresponds to Levothyroxine Sodium Tablets, 25 mcg, manufactured by Vesta Pharmaceuticals, Inc. This product is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypothyroidism [1]. Its approval history and current market presence are critical indicators of its established position within the therapeutic landscape.
FDA Approval and Market Entry
Levothyroxine Sodium Tablets, 25 mcg, were approved by the FDA under an Abbreviated New Drug Application (ANDA). This signifies that the product is a generic equivalent to a previously approved branded drug, meeting the same safety and efficacy standards. The specific FDA approval date for this strength and manufacturer is essential for understanding the duration of market exclusivity for the originator product and the subsequent entry of generics.
Data from the FDA's Orange Book, a database of FDA-approved drug products, indicates that Levothyroxine Sodium Tablets have a long history of FDA approval across various strengths. The product NDC 00173-0772, manufactured by Vesta Pharmaceuticals, Inc., has been actively marketed, suggesting it has met regulatory requirements for quality and manufacturing practices.
What Intellectual Property Protects NDC 00173-0772?
The intellectual property landscape for generic drugs like Levothyroxine Sodium Tablets revolves primarily around patents that may have protected the originator product and its manufacturing processes. For NDC 00173-0772, as a generic product, the key IP considerations are the expiration of patents held by the innovator company that first brought Levothyroxine Sodium to market.
Patent Expirations and Generic Competition
Levothyroxine Sodium has been a widely prescribed medication for decades. The primary originator product, Synthroid, manufactured by AbbVie (formerly Abbott Laboratories), has faced generic competition for an extended period. Key patents for Synthroid have long since expired, paving the way for multiple generic manufacturers to enter the market [2].
The patent landscape for Levothyroxine Sodium is complex due to its long history and the availability of multiple formulations and manufacturing processes. However, for a generic product like NDC 00173-0772, the critical factor is the absence of active patent protection that would prevent its marketing. This typically occurs after the expiration of all relevant patents, including those for the active pharmaceutical ingredient (API), specific salt forms, formulations, and methods of use.
Key Patent Considerations for Generic Levothyroxine:
- Compound Patents: Patents covering the levothyroxine molecule itself. These have long expired.
- Formulation Patents: Patents protecting specific tablet compositions, excipients, or delivery mechanisms.
- Process Patents: Patents covering novel methods of synthesizing levothyroxine or manufacturing the final dosage form.
- Use Patents: Patents protecting new therapeutic applications of the drug.
For NDC 00173-0772, Vesta Pharmaceuticals, Inc., would have developed its manufacturing process and formulation to be non-infringing of any remaining valid patents. This is a standard requirement for ANDA approval. The absence of any patent litigation or injunctions against Vesta Pharmaceuticals for this product indicates that its market entry and continued availability are not restricted by active IP claims from an originator.
What is the Market Size and Growth Projection for Levothyroxine Sodium?
The market for Levothyroxine Sodium is substantial and stable due to its status as a first-line treatment for hypothyroidism, a chronic condition affecting millions globally. The demand is driven by the prevalence of thyroid disorders and the drug's established safety and efficacy profile.
Market Dynamics and Demand Drivers
Hypothyroidism is a chronic condition characterized by insufficient production of thyroid hormones. Its prevalence has been increasing, contributing to a steady demand for levothyroxine. Factors influencing market growth include:
- Increasing Incidence of Thyroid Disorders: Growing awareness, improved diagnostic capabilities, and potential environmental factors contribute to higher diagnosis rates.
- Aging Population: Thyroid disorders are more common in older adults, a demographic that is expanding globally.
- Standard of Care: Levothyroxine remains the gold standard for hormone replacement therapy, ensuring consistent demand.
- Long-Term Treatment: Hypothyroidism requires lifelong treatment, creating a predictable and recurring market.
The market for levothyroxine is characterized by intense generic competition, which typically leads to price erosion. However, the sheer volume of prescriptions helps maintain a significant overall market value.
Pricing Trends and Projections
The pricing of generic Levothyroxine Sodium Tablets is heavily influenced by competition among manufacturers. With numerous generic players in the market, prices are generally low and have been subject to significant downward pressure over the years.
Factors Affecting Levothyroxine Pricing:
- Number of Generic Manufacturers: A high number of competitors drives down prices.
- Manufacturing Costs: Efficiency in API sourcing and tablet production impacts cost competitiveness.
- Wholesale Acquisition Cost (WAC): The list price from manufacturers, often subject to discounts.
- Pharmacy Benefit Manager (PBM) Negotiations: PBMs negotiate significant rebates and discounts, influencing net prices paid by payers.
- Contract Pharmacy Agreements: Large pharmacy chains and health systems secure preferential pricing through volume contracts.
Price Projections:
The market for Levothyroxine Sodium Tablets is expected to remain competitive. While absolute price increases are unlikely for the generic product category, slight fluctuations may occur due to supply chain dynamics, API cost variations, or strategic pricing by manufacturers to gain market share.
- Short-Term (1-3 years): Stable to slightly declining prices are projected due to ongoing competition. Average wholesale prices (AWP) or net prices paid by payers will likely remain at historically low levels.
- Mid-Term (3-5 years): Price stability is anticipated. Any significant price shifts would likely be driven by major supply disruptions or the introduction of novel therapeutic alternatives, which are not currently on the horizon for routine hypothyroidism management.
- Long-Term (5+ years): The market is expected to continue its mature trajectory. Pricing will remain a competitive factor, with manufacturers focusing on efficiency and reliable supply.
Estimated Market Value:
The global levothyroxine market is valued in the billions of dollars. While specific figures for NDC 00173-0772 alone are not publicly disaggregated, the overall levothyroxine market, encompassing all generics and strengths, is a significant segment of the endocrine drug market. For example, the broader U.S. market for levothyroxine, including all forms, is estimated to be over \$1.5 billion annually [3]. Generic levothyroxine constitutes the vast majority of this market value.
The 25 mcg strength is one of the most commonly prescribed dosages, contributing significantly to the overall volume and revenue. Vesta Pharmaceuticals, Inc.'s share of this market will depend on its manufacturing capacity, distribution network, and pricing strategy relative to its competitors.
What are the Competitive Threats to NDC 00173-0772?
The primary competitive threats to NDC 00173-0772 are other generic manufacturers producing Levothyroxine Sodium Tablets, as well as potential therapeutic advancements.
Direct Competition from Other Generic Manufacturers
The market for Levothyroxine Sodium Tablets is highly fragmented, with numerous pharmaceutical companies manufacturing and distributing generic versions. These competitors vie for market share based on price, product availability, and established relationships with distributors and pharmacies.
Major Generic Competitors (Examples):
- Teva Pharmaceuticals: A large global generic manufacturer with a broad portfolio.
- Hikma Pharmaceuticals: Another significant player in the generic drug market.
- Amneal Pharmaceuticals: A prominent U.S.-based generic and specialty pharmaceutical company.
- Sun Pharmaceutical Industries: A global leader in the pharmaceutical industry, with a strong generic presence.
- Apotex Inc.: A Canadian-based global pharmaceutical company.
These companies, along with many others, produce Levothyroxine Sodium Tablets in various strengths, including 25 mcg. The presence of multiple suppliers for the same dosage form creates intense pricing pressure.
Indirect Competition and Future Therapeutic Developments
While levothyroxine is the established standard of care, ongoing research in endocrinology could eventually lead to new treatment modalities for hypothyroidism. However, given the drug's efficacy, safety, and low cost, any new therapy would need to offer substantial advantages to displace levothyroxine.
Potential Future Developments:
- Novel Hormone Replacement Therapies: Research into alternative forms of thyroid hormone replacement or combinations that improve patient outcomes or reduce side effects.
- Regenerative Medicine Approaches: Long-term research into stimulating natural thyroid function.
- Personalized Medicine: Tailoring treatment based on genetic markers or individual metabolic profiles, though this is more likely to refine levothyroxine dosing than replace it entirely.
Currently, no significant pipeline drugs pose an immediate threat to the dominance of levothyroxine in the hypothyroidism market. The focus of competition remains on the generic market dynamics.
Key Takeaways
The market for NDC 00173-0772, Levothyroxine Sodium Tablets, 25 mcg, is characterized by a mature lifecycle, driven by consistent demand for a first-line treatment of hypothyroidism. Intellectual property protection for the originator product has long expired, allowing for robust generic competition. This competition has resulted in a highly price-sensitive market with significant volume. Vesta Pharmaceuticals, Inc., operates within this competitive landscape, where success is contingent on manufacturing efficiency, reliable supply, and strategic pricing. Future market performance will likely be stable, with pricing remaining a key determinant of market share.
Frequently Asked Questions
What is the primary indication for Levothyroxine Sodium Tablets?
Levothyroxine Sodium Tablets are primarily indicated for the treatment of hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones.
How does the patent status of originator drugs affect generic Levothyroxine Sodium?
The expiration of all relevant patents for originator Levothyroxine Sodium products allows for generic manufacturers like Vesta Pharmaceuticals, Inc., to enter the market and produce bioequivalent versions without infringing on intellectual property rights.
What factors contribute to the stability of the Levothyroxine Sodium market?
The market for Levothyroxine Sodium is stable due to the chronic nature of hypothyroidism, the drug's established efficacy and safety profile, and its status as the standard of care, ensuring continuous and predictable demand.
What is the competitive landscape for generic Levothyroxine Sodium?
The competitive landscape is highly fragmented, with numerous generic manufacturers producing Levothyroxine Sodium. Competition is primarily based on price, product availability, and established distribution channels.
What are the potential future threats to the Levothyroxine Sodium market?
While currently dominant, future threats could emerge from novel therapeutic approaches in endocrinology or advanced regenerative medicine, although these are not immediate concerns for the established levothyroxine market.
Citations
[1] U.S. Food and Drug Administration. (n.d.). FDA drug database. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/
[3] Global Market Insights. (2023). Levothyroxine Market Size, Share & Trends Analysis Report By Disease, By Formulation, By Dosage, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2032. Retrieved from https://www.gminsights.com/industry-analysis/levothyroxine-market
